Stratos Wealth Partners LTD. Has $428,000 Stake in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Stratos Wealth Partners LTD. raised its stake in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 48.3% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 6,926 shares of the company’s stock after purchasing an additional 2,255 shares during the period. Stratos Wealth Partners LTD.’s holdings in Amphastar Pharmaceuticals were worth $428,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. BlackRock Inc. boosted its stake in shares of Amphastar Pharmaceuticals by 1.1% in the 3rd quarter. BlackRock Inc. now owns 7,147,813 shares of the company’s stock valued at $200,854,000 after purchasing an additional 75,616 shares during the last quarter. Federated Hermes Inc. boosted its position in Amphastar Pharmaceuticals by 0.7% during the first quarter. Federated Hermes Inc. now owns 3,487,430 shares of the company’s stock valued at $125,199,000 after acquiring an additional 23,095 shares during the last quarter. Vanguard Group Inc. grew its holdings in Amphastar Pharmaceuticals by 1.8% during the 3rd quarter. Vanguard Group Inc. now owns 2,606,162 shares of the company’s stock worth $73,234,000 after acquiring an additional 45,385 shares during the period. Dimensional Fund Advisors LP raised its position in shares of Amphastar Pharmaceuticals by 2.7% in the 1st quarter. Dimensional Fund Advisors LP now owns 1,917,571 shares of the company’s stock worth $71,909,000 after acquiring an additional 51,027 shares in the last quarter. Finally, State Street Corp raised its position in shares of Amphastar Pharmaceuticals by 16.6% in the 2nd quarter. State Street Corp now owns 1,540,846 shares of the company’s stock worth $53,606,000 after acquiring an additional 218,895 shares in the last quarter. 65.09% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

AMPH has been the subject of several recent analyst reports. Needham & Company LLC reaffirmed a “hold” rating on shares of Amphastar Pharmaceuticals in a research note on Wednesday. JPMorgan Chase & Co. initiated coverage on shares of Amphastar Pharmaceuticals in a research report on Tuesday, March 5th. They set an “overweight” rating and a $60.00 price objective for the company. Finally, StockNews.com downgraded shares of Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, February 29th. Three research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Amphastar Pharmaceuticals has an average rating of “Hold” and a consensus target price of $66.00.

Insider Activity at Amphastar Pharmaceuticals

In other Amphastar Pharmaceuticals news, Director Floyd F. Petersen sold 500 shares of the business’s stock in a transaction that occurred on Thursday, February 1st. The stock was sold at an average price of $53.10, for a total transaction of $26,550.00. Following the completion of the sale, the director now directly owns 80,333 shares of the company’s stock, valued at approximately $4,265,682.30. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other Amphastar Pharmaceuticals news, Director Michael A. Zasloff sold 12,500 shares of the stock in a transaction dated Tuesday, March 5th. The shares were sold at an average price of $47.18, for a total value of $589,750.00. Following the completion of the sale, the director now owns 21,326 shares in the company, valued at approximately $1,006,160.68. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, Director Floyd F. Petersen sold 500 shares of Amphastar Pharmaceuticals stock in a transaction that occurred on Thursday, February 1st. The stock was sold at an average price of $53.10, for a total transaction of $26,550.00. Following the transaction, the director now directly owns 80,333 shares in the company, valued at approximately $4,265,682.30. The disclosure for this sale can be found here. In the last quarter, insiders have sold 14,000 shares of company stock valued at $660,860. 28.40% of the stock is owned by corporate insiders.

Amphastar Pharmaceuticals Stock Performance

NASDAQ AMPH opened at $39.62 on Friday. The company has a market cap of $1.91 billion, a P/E ratio of 15.36, a PEG ratio of 0.96 and a beta of 0.84. The company has a fifty day simple moving average of $47.31 and a 200 day simple moving average of $51.35. The company has a current ratio of 2.17, a quick ratio of 1.70 and a debt-to-equity ratio of 0.92. Amphastar Pharmaceuticals, Inc. has a 12-month low of $35.62 and a 12-month high of $67.66.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last released its quarterly earnings data on Wednesday, February 28th. The company reported $0.81 earnings per share for the quarter, missing analysts’ consensus estimates of $0.84 by ($0.03). The business had revenue of $178.11 million during the quarter, compared to the consensus estimate of $174.90 million. Amphastar Pharmaceuticals had a net margin of 21.34% and a return on equity of 26.95%. Sell-side analysts predict that Amphastar Pharmaceuticals, Inc. will post 3.42 earnings per share for the current fiscal year.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.